| Name | Title | Contact Details |
|---|---|---|
Robert Georgantas |
President and Chief Technology Officer | Profile |
BioReliance Corporation is a contract service organization that provides services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company has two segments, testing and development services and
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Use this space to add a brief description of your project.
Celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform.
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a completely new category in therapeutics.